CSV February 23, 2023 through February 23, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
GLUTARAL CO ASSAY/		*USP40–NF35*	4414	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second*	Line 7 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NCENTRATE	*Procedure*						*Supplement to USP41–NF36*	*Analysis*: Change Add a weighed quantity of Concentrate containing 1.2 g of glutaral by means of a suitable weighing pipet. to: Add 1.2 g of Glutaral Concentrate.
MYCOPHENOLIC ACID DELAYED-RELEASE TABLETS	IMPURITIES/*Organic Impurities*	*USP40–NF35*	5257	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Change *Mobile phase*, *Standard solution*, *Sample solution*, and *Chromatographic system*: to: *Mobile phase*, *Diluent*, *Standard solution*, *Sample solution*, and *Chromatographic system*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ISOSORBIDE DINITRATE EXTENDED-RELEASE TABLETS	*Assay*	*USP40–NF35*	4710	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Change *Buffer solution*, *Mobile phase*, *Internal standard solution*, *Standard preparation*, and *Chromatographic system*—Prepare as directed in the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Buffer solution*—Dissolve 15.4 g of ammonium acetate in water, add 11.5 mL of glacial acetic acid, dilute with water to 1000 mL, and mix to obtain a solution having a pH of about

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								4.7. *Mobile phase*—Mix 350 mL of water, 100 mL of *Buffer solution*, and 550 mL of methanol. Cool to room temperature, dilute with water to 1000 mL, mix, degas, and filter. Make adjustments if necessary (see *System Suitability* under *Chromatography <621>*). *Internal standard solution*—Transfer a quantity of diluted nitroglycerin to a suitable volumetric flask, add about 60% of the flask

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								volume of methanol, sonicate for 5 minutes, and shake for 30 minutes. Dilute with methanol to volume to obtain a solution having a concentration of about 3 mg of nitroglycerin per mL, and mix. Allow any undissolved material to settle, filter, and store the filtrate in an airtight container. *Standard prep aration* —Transfer about 125 mg of recently mixed USP Diluted Isosorbide Dinitrate RS, accurately

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								weighed, to a 50-mL volumetric flask, add about 30 mL of *Mobile phase*, shake for 30 minutes, dilute with *Mobile phase* to volume, and mix. Pipet 10 mL of the resulting solution into a 25-mL volumetric flask, and add 4.0 mL of *Internal standard solution* and 4 mL of dilute *Buffer solution* (1 in 10). Cool to room temperature, dilute with *Mobile phase* to volume, and mix to obtain a solution having a known

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								concentration of about 0.25 mg of isosorbide dinitrate per mL, based on the quantity of USP Diluted Isosorbide Dinitrate RS weighed and the labeled content of isosorbide dinitrate. Pass a portion of this solution through a 0.45-µm filter. AND Change *Proce dure*—Proceed as directed for *Procedure* in the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Chromatographi c system* (see *Chromatograph*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								y <*621*>)—The liquid chromatograph is equipped with a 220-nm detector and a 4-mm × 25-cm column that contains packing L1. The flow rate is about 1 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between isosorbide dinitrate and nitroglycerin is not less than 2.0; and the relative standard deviation for replicate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								injections determined from the peak response ratios is not more than 2%. [NOTE—The relative retention times are about 0.75 for isosorbide dinitrate and 1.0 for nitroglycerin. The relative retention times for isosorbide mononitrates, if present, are about 0.38.] *Procedure*—Separately inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								record the chromatograms, and measure the responses for the major peaks.
MYCOPHENOLATE MOFETIL FOR ORAL SUSPENSION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP40–NF35*	5251	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Mycophenolate Mofetil Related Compound B RS: Change (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuranyl-1-one. to: (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuran-1-one.
POWDERED A	COMPOSITION	*USP40–NF35*	6804	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First*	Add

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SHWAGANDHA ROOT EXTRACT	*/Content of Withanolides*						*Supplement to USP41–NF36*	*Solution B*: Acetonitrile, filtered and degassed
EFAVIRENZ	SPECIFIC TESTS/ *Enantiomeric Purity*	*Second Supplement to USP40–NF35*	Online	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Mobile phase*: Change Hexane and ethanol (97:3) to: Hexane and absolute alcohol (97:3)
REAGENTS, INDICATORS AND SOLUTIONS	S OL UTION S/*Volumetric Solutions*/*1 N Sulfuric Acid VS*	*USP40–NF35*	2434	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 3 of *Standardization*: Change dried at 150° to: dried at 105°
GADOTERIDOL	*Chromatographic purity*/*Test 2 (Nongadolinium-Containing Impurities)*	*USP40–NF35*	4360	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *pH 5.0 Buffer*: Change *50 mM Ammonium* to: *50 mM Ammonium phosphate buffer* AND Line 1 of *pH 7.0 Buffer*: Change *50 mM*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Ammonium to: *50 mM Ammonium phosphate buffer*
MEMANTINE HYDROCHLORIDE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Analysis*	*USP40–NF35*	5000	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	In the variable definition list: Change C_S = concentration of USP Memantine Hydrochloride RS in the *Standard solution* (µg/mL) to: C_S = concentration of USP Memantine Hydrochloride RS in the *Standard stock solution* (mg/mL)
PEMETREXED DISODIUM	IMPURITIES/*Organic Impurities*/*Table*	*USP40–NF35*	5588	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Footnote b: Change {4-[2-(2-Amino-1-methyl-4-oxo-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	2							4, 7-di hydro-1*H* -pyr rolo[2,3 -*d*]pyrimidin-5-yl)e thyl]benzoyl}-4- L-glutamyl-L- glutamic acid. to: {4?[2?(2?Amino ?4?oxo?4,7?dih ydro?1*H* ?p yrrolo [2,3?*d*]pyrimidin?5?yl) ethyl]benzoyl}?4 ?L?glutamyl?L? glutamic acid.
FLUVOXAMINE MALEATE	CHEMICAL INFORMATION	*Second Supplement to USP40–NF35*	8797	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 4:Change 5-Methoxy-4’-(t rifluoromethyl)v alerophenone (*E*)-*O* -(2-aminoethyl) oxime, maleate (1:1) to: (*E*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-5-Methoxy-4’-(trifluoromethyl) valerophenone *O* -(2-aminoethyl) oxime, maleate (1:1)
ENOXAPARIN SODIUM INJECTION	SPECIFIC TESTS/*Anti-Factor IIa Activity*	*USP40–NF35*	3982	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Delete *Standard solutions*: Dilute USP Enoxaparin Sodium Solution for Bioassays RS with *pH 7.4 buffer* to obtain four dilutions having concentrations in the range between 0.015 and 0.075 IU of Anti-Factor IIa activity/mL.
ISOSORBIDE DINITRATE EXTENDED-RELEASE TABLETS	*Dissolution <711>/Test 2*	*USP40–NF35*	4710	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1: Change *Buffer solution* and *Mobile phase*—Prepare as directed in the *Assay* under

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Diluted Isosorbide Dinitrate. to: *Buffer solution* and *Mobile phase*—Prepare as directed in the *Assay*. AND Line 1 of *Chromatographic system*: Change (see *Chromatography <621>*)—Proceed as directed in the *Assay* under *Diluted Isosorbide Dinitrate*. to: (see *Chromatography <621>*)—Proceed as directed in the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Assay.
MYCOPHENOLATE SODIUM	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP40–NF35*	5256	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Mycophenolate Mofetil Related Compound B RS: Change (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H* -isobenzofuranyl-1-one. to: (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H* -isobenzofuran-1-one.
MONOBASIC POTASSIUM PHOSPHATE	IMPURITIES/*Arsenic, Method I <211>*	*USP40–NF35*	7847	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1: Change 3 µg/g to: NMT 3 µg/g
POTASSIUM CITRATE EXTE	ASSAY/*Procedure*	*Revision Bulletin (Official*	Online	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to*	Line 1 of *Chromatographi*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NDED-RELEASE TABLETS		*April 01, 2017)*					*USP41–NF36*	*c* *system*/*Column*: Change 10-µm to: 5-µm AND In the variable definition list in *Analysis*: Change r_U = citrate peak area from the *Sample solution* r_S = citrate peak area from the *Standard solution* to: r_U = citric acid peak area from the *Sample solution* r_S = citric acid peak area from the *Standard solution* AND Change M_{r2} = molecular weight of citrate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								($C_6H_5O_7$), 189.10 to: M_{r2} = molecular weight of citric acid ($C_6H_8O_7$), 192.13
CALCIPOTRIENE OINTMENT	IMPURITIES/*Organic Impurities*	*USP40–NF35*	3114	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Footnote a of *Table 1*: Change (5*Z*,7*Z*,22*E*,24*R*)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1?,3?,24-triol. to: (5*Z*,7*Z*,22*E*,24*S*)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1?,3?,24-triol.
ISOSORBIDE DINITRATE EXTENDED-RELEASE CAPSULES	*Assay*	*USP40–NF35*	4708	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Change *Buffer solution*, *Mobile phase*, *Internal standard solution*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard preparation, and *Chromatographic system*—Prepare as directed in the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Buffer solution*—Dissolve 15.4 g of ammonium acetate in water, add 11.5 mL of glacial acetic acid, dilute with water to 1000 mL, and mix to obtain a solution having a pH of about 4.7. *Mobile phase*—Mix 350 mL of water, 100 mL of *Buffer solution*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and 550 mL of methanol. Cool to room temperature,dilute with water to 1000 mL, mix, degas,and filter. Make adjustments if necessary (see *System Suitability* under *Chromatography <621>*). *Internal standard solution* —Transfer a quantity of diluted nitroglycerin to a suitable volumetric flask, add about 60% of the flask volume of methanol, sonicate for 5 minutes, and shake for 30

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								minutes. Dilute with methanol to volume to obtain a solution having a concentration of about 3 mg of nitroglycerin per mL, and mix. Allow any undissolved material to settle, filter, and store the filtrate in an airtight container. *Standard prep aration* —Transfer about 125 mg of recently mixed USP Diluted Isosorbide Dinitrate RS, accurately weighed, to a 50-mL volumetric flask, add about 30 mL of *Mobile*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								phase, shake for 30 minutes, dilute with *Mobile phase* to volume, and mix. Pipet 10 mL of the resulting solution into a 25-mL volumetric flask, and add 4.0 mL of *Internal standard solution* and 4 mL of dilute *Buffer solution* (1 in 10). Cool to room temperature, dilute with *Mobile phase* to volume, and mix to obtain a solution having a known concentration of about 0.25 mg of isosorbide dinitrate per mL, based on the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								quantity of USP Diluted Isosorbide Dinitrate RS weighed and the labeled content of isosorbide dinitrate. Pass a portion of this solution through a 0.45-µm filter. AND Change *Proce dure*—Proceed as directed for *Procedure* in the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Chromatographi c system* (see *Chromatograph y <621>*)—The liquid chromatograph is equipped with a 220-nm

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								detector and a 4-mm × 25-cm column that contains packing L1. The flow rate is about 1 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between isosorbide dinitrate and nitroglycerin is not less than 2.0; and the relative standard deviation for replicate injections determined from the peak response ratios is not more than

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								2%. [NOTE—The relative retention times are about 0.75 for isosorbide dinitrate and 1.0 for nitroglycerin. The relative retention times for isosorbide mononitrates, if present, are about 0.38.] *Procedure*—Separately inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								peaks.
MYCOPHENOLATE MOFETIL FOR INJECTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP40–NF35*	5250	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Mycophenolate Mofetil Related Compound B RS: Change (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuranyl-1-one. to: (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuran-1-one.
PEMETREXED FOR INJECTION	ASSAY/*Procedure/Analysis*	*USP40–NF35*	5590	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	In the variable definition list: Change M_{r2} = molecular weight of pemetrexed

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								disodium, 597.49 to: M_{r2} = molecular weight of pemetrexed disodium (anhydrous), 473.37
FLUVOXAMINE MALEATE	IMPURITIES/*Organic Impurities*/*Table 1*	*Second Supplement to USP40–NF35*	8797	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Footnote b:Change 5-Methoxy-1-[4-(trifluoromethyl) phenyl]-1-pentanone (*E*)-*O*-[2-[(2-succinyl) amino]ethyl]oxime. to: (*E*)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone *O*-[2-[(2-succinyl) amino]ethyl]oxime. AND Footnotes c– g: Delete the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								space before oxime
REAGENTS	REAGENT SPE *Brom elain/Activity Determination*	*USP40–NF35*	2339	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Buffer solution*: Change Add 150 mg of sodium chloride to: Add 150 g of sodium chloride
FENOLDOPAM MESYLATE	*USP Reference standards <11>*	*USP40–NF35*	4159	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Fenoldopam Related Compound A RS: Change 1-Methyl-3-benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-, methanesulfonate (salt). $C_{17}H_{18}ClNO_3 \cdot CH_4SO_3$ 415.89 to: 6-Chloro-1-(4-hydroxyphenyl)-3-methyl-2,3,4,5-tetr ahydro -1*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-benzo[*d*]azepine-7,8-diol hydrochloride (*N*-Methyl-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1*H*-3-benzazepine-7,8-diol hydrochloride). $C_{17}H_{19}ClNO_3 \cdot HCl$ 356.24
MEBENDAZOLE	IMPURITIES/*Organic Impurities*/*Table 2*	*USP40–NF35*	4968	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Change footnotes [d]Ethyl 5-benzoyl-1-methylbenzimidazol-2-ylcarbamate. [e]Methyl 5-(4-toluoyl)-1-methylbenzimidazol-2-ylcarbamate. to: [d]Ethyl (5-benzoyl-1*H*-benzimidazol-2-yl)carbamate.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MYCOPHENOLATE SODIUM	IMPURITIES/*Organic Impurities*	*USP40–NF35*	5256	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	[e]Methyl 5-(4-toluoyl)-1*H*-benzimidazol-2-ylcarbamate. Footnote a of *Table 2*: Change (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuranyl-1-one. to: (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuran-1-one.
CANDESARTAN CILEXETIL	ADDITIONAL REQUIREMENT	*Second Supplement to*	8730	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to*	Line 2 of USP Candesartan

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS	S/*USP Reference Standards <11>*	*USP40–NF35*					*USP41–NF36*	Cilexetil Related Compound D RS: Change 1-{[(Cyclohexyloxycarbonyloxy)carbonyl]oxy}ethyl
								H-tetrazol-5-yl)biphenyl-4-yl]methyl}-2-oxo-2,3-dihydro-1*H*-benzimidazole-4-carboxylate. to: 1-{[(Cyclohexyloxy)carbonyl]oxy}ethyl
								H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl}methyl)-2-oxo-2,3-dihydro-1*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-benzimidazole-4-carboxylate.
ENALAPRIL MALEATE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Table 1*	*USP40–NF35*	3971	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Row 3 of Column 3: Change 100 to: 200
ONDANSETRON INJECTION	*USP Reference standards <11>*	*USP40–NF35*	5443	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Ondansetron Related Compound A RS: Change 3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one. to: 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride.
ROCURONIUM BROMIDE	IMPURITIES/*Limit of*	*USP40–NF35*	6066	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of the variable definition list:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	2-Propanol/Analysis							Change r_U = peak response of any impurity from the *Sample solution* r_S = peak response of rocuronium bromide from the *Dilute standard solution* to: r_U = peak response of 2-propanol from the *Sample solution* r_S = peak response of 2-propanol from the *Dilute standard solution*
OIL- AND WATER-SOLUBLE VITAMINS CAPSULES	STRENGTH	*USP40–NF35*	7290	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Vitamin A, Method 1*/*Sample solution*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Sample solution to: *Sample stock solution* AND Line 23 of *Sample solution*: Change Dilute a volume of this solution to: *Sample solution*: Dilute a volume of the *Sample stock solution* AND Line 1 of *Cholecalciferol or Ergocalciferol (Vitamin D), Method 1/Sample solution*:Change Proceed as directed for the *Sample solution* to: Proceed as directed for the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MONOSACCH	PROCEDURES	*First*	8059	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First*	*Sample stock solution* AND Line 1 of *Vitamin E, Method 1*/*Sample solution*: Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution* AND Line 2 of *Phytonadione/Sample solution*:Change in the directions for the *Sample solution* to: in the directions for the *Sample stock solution* Line 6 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ARIDE ANALYSIS	/*Procedure 3: Enzymatic Hydrolysis and Analysis by RP-HPLC of DMB-labeled Sialic Acids*	*Supplement to USP40–NF35*					*Supplement to USP41–NF36*	*Analysis*: Change (1 M = 1nmol/mL). to: (1 µM = 1nmol/mL).
LEVOTHYROXINE SODIUM TABLETS	IM PURITIES/*Limit of Liothyronine Sodium*	*First Supplement to USP40–NF35*	8328	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 4 of *Analysis*: Change Calculate the percentage of levothyroxine sodium ($C_{15}H_{11}I_3NNaO_4$) to: Calculate the percentage of liothyronine sodium ($C_{15}H_{11}I_3NNaO_4$)
DOXAZOSIN MESYLATE	ASSAY/*Procedure*/*System suitability*/*Suitability requirements*	*USP40–NF35*	3874	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Resolution*: Change NLT 4 to: NLT 2
PERPHENAZINE	IM PUR	*USP40–NF35*	5649	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to*	Line 1 of *Column*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	ITIES/*Organic Impurities/ Chromatographic system*						*USP41–NF36*	Change 4.6-mm to: 4.0-mm
OIL-SOLUBLE VITAMINS WITH MINERALS CAPSULES	STRENGTH	*USP40–NF35*	7265	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Vitamin A*/*Sample solution*: Change *Sample solution* to: *Sample stock solution* AND Line 21 of *Sample solution*: Change Further dilute this solution to: *Sample solution*: Dilute the *Sample stock solution* AND Line 2 of *Vitamin D*/*Sample solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change as directed for the *Sample solution* to: as directed for the *Sample stock solution* AND Line 2 of *Vitamin E*/*Sample solution*: Change prepared as directed for the *Sample solution* to: prepared as directed for the *Sample stock solution* AND Line 2 of *Phytonadione (Vitamin K_1)*:Change as directed for the *Sample solution* to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								as directed for the *Sample stock solution* AND Line 2 of *Beta Carotene*/*Sample solution*: Change as directed for the *Sample solution* to: as directed for the *Sample stock solution*
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS TABLETS	STRENGTH	*USP40–NF35*	7375	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Vitamin A, Method 1*/*Sample solution*: Change *Sample solution* to: *Sample stock solution* AND Line 16 of *Sample solution*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Dilute a 10-mL volume of this solution to: *Sample solution*: Dilute a 10-mL volume of the *Sample stock solution* AND Line 2 of *Cholecalciferol or Ergocalciferol (Vitamin D), Method 1*/*Sample solution*: Change prepared as directed for the *Sample solution* to: prepared as directed for the *Sample stock solution* AND Line 2 of *Vitamin E, Method 1*/*Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution: Change prepared as directed for the *Sample solution* to: prepared as directed for the *Sample stock solution* AND Line 2 of *Phytonadione, Method 1*/*Sample solution*: Change prepared as directed for the *Sample solution* to: prepared as directed for the *Sample stock solution*
ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS	PERFORMANCE TESTS	*First Supplement to USP40–NF35*	8202	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Dissolution <711>*/*Analysis*:Change Determine the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								labeled amount of acetaminophen to: Determine the percentage of the labeled amount of acetaminophen AND In the second Calculate statement in *Uniformity of Dosage Units <905>/ Procedure for content unifor mity/Analysis*: Change Calculate the quantity, in mg/mL, of the labeled amount of codeine phosphate to: Calculate the quantity, in mg, of codeine

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TIMOLOL MALEATE	MULTIPLE SECTIONS	*Second Supplement to USP40–NF35*	Online	28-Jul-2017	1-Aug-2017	*USP41–NF36*	*USP41–NF36*	phosphate The version of the Timolol Maleate monograph which appeared in the *Second Supplement to USP 40–NF 35* did not include the revisions approved in the version appearing in the *First Supplement to USP 40–NF 35*. The version appearing in the *First Supplement* should be used. The file as it should have appeared in the *Second Supplement* is attached to the compendial notice found at http://www.uspn

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								f.com/notices/second-supplement-usp-40-nf-35-online-timolol-maleate.
ONDANSETRON ORAL SOLUTION	*USP Reference standards <11>*	*USP40–NF35*	5444	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Ondansetron Related Compound A RS: Change 3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one. to: 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride.
OIL-SOLUBLE VITAMINS CAPSULES	STRENGTH	*USP40–NF35*	7248	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Vitamin A, Method 1*/*Sample solution*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Sample solution to: *Sample stock solution* AND Line 23 of *Sample solution*: Change Dilute a volume of this solution to: *Sample solution*: Dilute a volume of the *Sample stock solution* AND Line 1 of *Cholecalciferol or Ergocalciferol (Vitamin D), Method 1/Sample solution*:Change Proceed as directed for the *Sample solution* to: Proceed as directed for the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Sample stock solution AND Line 1 of *Vitamin E, Method 1*/*Sample solution*: Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution* AND Line 1 of *Phytonadione/Sample solution*:Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution*
OIL- AND WAT	STRENGTH	*USP40–NF35*	7318	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First*	Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ER-SOLUBLE VITAMINS TABLETS							*Supplement to USP41–NF36*	*Vitamin A, Method 1*/*Sample solution*: Change *Sample solution* to: *Sample stock solution* AND Line 16 of *Sample solution*: Change Dilute a 10-mL volume of this solution to: *Sample solution*: Dilute a 10-mL volume of the *Sample stock solution* AND Line 1 of *Cholecalciferol or Ergocalciferol (Vitamin D), Method 1*/*Sample solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution* AND Line 1 of *Vitamin E, Method 1*/*Sample solution*: Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution* AND Line 2 of *Phytonadione, Method 1*/*Sample solution*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								retained as specified in the directions for the *Sample solution* to: retained as specified in the directions for the *Sample stock solution*
NEOTAME	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP40–NF35*	8485	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Neotame Related Compound A RS: Change *N*-[3,3-Dimethylbutyl)-L-?-aspartyl]-L-phenylalanine. to: *N*-[*N*-(3,3-Dimethylbutyl)-L-?-aspartyl]-L-phenylalanine.
ONDANSETRON HYDROCHLORIDE	*USP Reference standards <11>*	*USP40–NF35*	5441	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Ondansetron Related Compound A

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								RS: Change 3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one. to: 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride.
PROPANTHELINE BROMIDE	IMPURITIES/*Organic Impurities/ Chromatographic system*	*USP40–NF35*	5882	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Run time*: Change NMT to: NLT
OIL-SOLUBLE VITAMINS WITH MINERALS TABLETS	STRENGTH	*USP40–NF35*	7280	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Vitamin A*/*Sample solution*: Change *Sample solution* to: *Sample stock*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution AND Line 15 of *Sample solution*: Change Further dilute this solution to: *Sample solution*: Dilute the *Sample stock solution* AND Line 2 of *Vitamin D*/*Sample solution*: Change as directed for the *Sample solution* to: as directed for the *Sample stock solution* AND Line 2 of *Vitamin E*/*Sample solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change prepared as directed for the *Sample solution* to: prepared as directed for the *Sample stock solution* AND Line 2 of *Phytonadione (Vitamin K_1)*:Change as directed for the *Sample solution* to: as directed for the *Sample stock solution* AND Line 2 of *Beta Carotene*/*Sample solution*: Change as directed for the *Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution to: as directed for the *Sample stock solution*
SHELLAC	IM PURITIES/*Limit of Chloride*	*USP40–NF35*	7869	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Control solution*: Change 0.1 M hydrochloric acid VS, to: 0.01 M hydrochloric acid VS,
ERYTHROMYCIN OPHTHALMIC OINTMENT	ASSAY/*Procedure/Analysis*	*First Supplement to USP40–NF35*	8276	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 9 of the third variable definition list: Change *P* = potency of erythromycin C in USP Erythromycin B RS (mg/mg) to: *P* = potency of erythromycin C in USP Erythromycin C RS (mg/mg)
VITAMIN D	ASSAY/	*USP40–NF35*	462	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First*	*Clean-up chrom*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ASSAY	*Chromatographic Methods/Procedure 8*						*Supplement to USP41–NF36*	*atographic system*: Add *Flow rate*: 1.1 mL/min AND *Analytical chromatographic system*: Add *Flow rate*: 1.0 mL/min
ONDANSETRON TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP40–NF35*	5445	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Ondansetron Related Compound A RS: Change 3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one. to: 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride.
OIL-SOLUBLE	STRENGTH	*USP40–NF35*	7258	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First*	Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
VITAMINS TABLETS							*Supplement to USP41–NF36*	*Vitamin A, Method 1*/*Sample solution*: Change *Sample solution* to: *Sample stock solution* AND Line 16 of *Sample solution*: Change Dilute a 10-mL volume of this solution to: *Sample solution*: Dilute a 10-mL volume of the *Sample stock solution* AND Line 2 of *Cholecalciferol or Ergocalciferol (Vitamin D), Method 1*/*Sample solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution* AND Line 1 of *Vitamin E, Method 1*/*Sample solution*: Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution* AND Line 2 of *Phytonadione, Method 1*/*Sample solution*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								retained as specified in the directions for *Sample solution* to: retained as specified in the directions for *Sample stock solution*

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 18
- Page 19
- Page 20
- Page 21
- Page 22
- Page 23
- Page 24
- Page 25
- Page 26
- …
- Next page Next ›
- Last page Last »